Sulbactam
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2969 publications
An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant gram-negative pathogens.
Journal: Expert opinion on drug metabolism & toxicology
Published: June 19, 2026
Characterizing the V516M penicillin-binding protein 2 (PBP2) mutation causing zidebactam resistance in Pseudomonas aeruginosa.
Journal: Antimicrobial agents and chemotherapy
Published: June 15, 2026
Cefoperazone/sulbactam-induced coagulopathy following pancreatic surgery
Journal: Khirurgiia
Published: June 15, 2026
Consistent in vitro activity of sulbactam-durlobactam against genetically diverse carbapenem-resistant Acinetobacter baumannii in a high-endemic Brazilian setting.
Journal: Antimicrobial agents and chemotherapy
Published: June 12, 2026
Clinical Outcomes of High-Dose Ampicillin-Sulbactam Combined with Colistin in the Treatment of Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii.
Journal: Microbial drug resistance (Larchmont, N.Y.)
Published: May 08, 2026
Transcriptome-constrained genome-scale metabolic modeling reveals central carbon and amino acid metabolic reprogramming underlying colistin-sulbactam synergy in Acinetobacter baumannii.
Journal: Antimicrobial agents and chemotherapy
Published: May 05, 2026
Glutamine Potentiates Cefoperazone-Sulbactam against Klebsiella pneumoniae by Enhancing Cellular Uptake and ROS Production.
Journal: ACS infectious diseases
Published: April 29, 2026
Sulbactam-Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii: A Narrative Review.
Journal: Antibiotics (Basel, Switzerland)
Published: April 14, 2026
Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease.
Journal: Antimicrobial agents and chemotherapy
Published: April 09, 2026
Case report: Delayed onset rash, delirium, and cross allergic reactions caused by sequential administration of cefoperazone sulbactam, meropenem, and piperacillin tazobactam.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: April 01, 2026
Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023-2025).
Journal: Microbiology spectrum
Published: March 23, 2026
Polymyxin B-associated hearing impairment in a patient with renal dysfunction- a case report.
Journal: BMC nephrology
Published: March 13, 2026
Last Updated: 06/30/2026